Treatment and outcome in children with tuberculous meningitis – a multi-centre Paediatric Tuberculosis Network European Trials Group study

Stephanie Thee 1*, Robindra Basu Roy 2*, Daniel Blázquez-Gamero 3, Lola Falcón-Neyra 4, Olaf Neth 4, Antoni Noguera-Julian 5,6,7,8, Cristina Lillo 3, Luisa Galli 9,10, Elisabetta Venturini 9,10, Danilo Buonsenso 11, Florian Götzinger 12, Nuria Martinez-Alier 13, Svetlana Velizarova 14, Folke Brinkmann 15, Steven B Welch 16, Maria Tsolia 17, Begoña Santiago-Garcia 18, Ralph Schilling 19,20, Marc Tebruegge 13,21,22**, Renate Krüger 1**, on behalf of the ptbnet TB Meningitis Study Group ***

1. Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Centre, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2. Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK.
3. Paediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Instituto de Investigación Hospital Universitario 12 de Octubre (imas12), RITIP, Madrid, Spain.
4. Paediatric Infectious Diseases, Rheumatology and Immunology Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Seville (IBIS), Sevilla, Spain.
5. Malalties Infecciooses i Resposta Inflamatòria Sistèmica en Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
6. Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain.
7. CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.
9. Department of Health Sciences, University of Florence, Florence, Italy.
10. Paediatric Infectious Disease Unit, Meyer Children’s University Hospital, Florence, Italy.
12. Department of Paediatrics and Adolescent Medicine, National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna, Austria
13. Department of Paediatric Infectious Diseases & Immunology, Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
14. Department of Pulmonary Diseases, Medical University, Hospital for Lung Diseases ‘St. Sofia’, Sofia, Bulgaria.
15. Department of Paediatric Pulmonology, Ruhr University Bochum, Bochum, Germany.
16. Birmingham Chest Clinic and Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK.
17. Second Department of Paediatrics, National and Kapodistrian University of Athens, School of Medicine, P. and A. Kyriakou Children’s Hospital, Athens, Greece.
19. Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Germany.
20. Institute for Social Medicine, Epidemiology and Health Economics, Charité – Universitätsmedizin Berlin, Germany.
21. Department of Paediatrics, Royal Children’s Hospital Melbourne, University of Melbourne, Melbourne, Australia.
22. Department of Infection, Immunity & Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.

* joint first authors; ** joint last authors

*** ptbnet TB Meningitis Study Group:
Matthias Bogyi, Wilhelminenspital Vienna, Austria; Carlotta Montagnani, Anna Meyer Children's University Hospital Florence, Italy; Laura Lancella, Bambino Gesù Children Hospital Rome, Italy; Eeva Salo, University of Helsinki Children's Hospital, Finland; Angeliki Syngelou, 2nd Dept of Paediatrics, National & Kapodistrian University of Athens, P. & A. Kyriakou Children’s Hospital, Greece; Uros Krivec, University Children's Hospital Ljubljana, Slovenia; Andrea Martín Nalda and Antoni Soriano-Arandes, Hospital Vall d’Hebron Barcelona, Spain; Irene Rivero, Hospital Clínico Universitario de Santiago de Compostela, Spain; Marta Benavides Nieto, Hospital Infantil Virgen del Rocío Sevilla, Spain; Mercedes Bueno, Hospital Universitario Fundación Alcorcón Madrid, Spain; Teresa del Rosal, Hospital Infantil La Paz Madrid, Spain; Luis Mayol and Borja Guarch, Hospital Universitari Dr. Josep Trueta Girona, Spain; Jose Antonio Couceiro, Complejo Hospitalario de Pontevedra, Spain; Carmelo Guerrero Laleona, Hospital Miguel Servet Zaragoza, Spain; Rutger Bennet, Astrid Lindgren Children’s Hospital Stockholm, Sweden; Karsten Kötz, Queen Silvia Children’s Hospital Gothenburg, Sweden; Brittany Raffa, Evelina London Children’s Hospital, UK; Fiona Shackley, Sheffield Children’s Hospital, UK.
Corresponding author
Stephanie Thee MD, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Phone: +49-30-450566182; Fax: +49-30-450566931; E-Mail: stephanie.thee@charite.de

Alternative corresponding author
Renate Krüger MD, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Phone: +49-30-450566182; Fax: +49-30-450566931; E-Mail: r.krueger@charite.de

Brief summary
This European multi-center study provides data on the management and outcome of TB meningitis in children, highlighting that both morbidity and mortality remain high even in high-resource settings. Several key factors associated with unfavourable outcome were identified.
Abstract

Introduction
Currently, data on treatment, outcome, and prognostic factors in children with tuberculous meningitis (TBM) in Europe are limited. To date, most existing data on TBM originate from adult studies, or studies conducted in low-resource settings.

Methods
Multicentre, retrospective study involving 27 paediatric healthcare institutions in nine European countries via an established paediatric TB research network, before and after the 2014 revision of WHO dosing recommendations.

Results
Of 118 children, 39 (33.1%) had TBM grade 1, 68 (57.6%) grade 2 and 11 (9.3%) grade 3. Fifty-eight (49.1%) children received a standard four-drug treatment regimen; other commonly used drugs included streptomycin, prothionamide, and amikacin. Almost half of the patients (48.3%; 56/116) were admitted to intensive care unit, with a median stay of 10 (IQR 4.5-21.0) days. Of 104 children with complete outcome data, 9.6% (10/104) died, and only 47.1% (49/104) recovered fully. Main long-term sequelae included spasticity of one or more limbs and developmental delay both in 19.2% (20/104), and seizure disorder in 17.3% (18/104). Multivariate regression analyses identified microbiological confirmation of TBM, the need for neurosurgical intervention and mechanical ventilation as risk factors for unfavourable outcome.

Discussion
There was considerable heterogeneity in the use of TB drugs in this cohort. Despite few children presenting with advanced disease and the study being conducted in a high-resource setting, morbidity and mortality were high. Several risk factors for poor outcome were identified, which may aid prognostic predictions in children with TBM in the future.
List of abbreviations

AMK    amikacin
BCG    *Bacillus Calmette-Guérin*
CI     confidence interval
CSF    cerebrospinal fluid
EMB    ethambutol
GCS    Glasgow coma scale
ICU    intensive care unit
IGRA   Interferon-γ release assay
INH    isoniazid
IQR    interquartile range
MDR    multidrug-resistant
MRC    Medical Research Council
MRI    magnetic resonance imaging
NAAT   nucleic acid amplification test
OR     odds ratio
ptbnet Paediatric Tuberculosis Network European Trials Group
PTH    prothionamide
PZA    pyrazinamide
RMP    rifampicin
SM     streptomycin
TB     tuberculosis
TBM    tuberculous meningitis
TST    tuberculin skin test
WHO    World Health Organization

Key words
Tuberculous meningitis, treatment, dosing, children, outcome
Introduction

In 2018, 52,862 cases of tuberculosis (TB) were reported in the European Union and European Economic Area, of which 4.0% were children <15 years-of-age (1). After TB lymphadenitis, tuberculous meningitis (TBM) is the most common form of extrapulmonary TB in children (2). TBM is associated with higher morbidity and mortality than any other form of focal TB disease (3, 4) (5). TBM diagnosis can be challenging because the onset is often insidious with non-specific symptoms, and classic meningitic symptoms can be absent. Advanced clinical stage at presentation is associated with higher mortality and morbidity: rates of death or severe disability are up to 50% in British Medical Research Council (MRC) grade III TBM despite appropriate treatment (5-9).

The current World Health Organization (WHO) treatment recommendation for children with drug-susceptible TBM comprises isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA) and ethambutol (EMB) for the initial 2 months, followed by 10 months of INH and RMP (10). This recommendation is adapted from pulmonary TB treatment and based on limited evidence (11). In view of mounting evidence that the drug doses recommended in the 2006 WHO guidelines achieved only suboptimal serum concentrations in children, higher doses were recommended in a WHO Rapid Advice document in 2010, and subsequently incorporated formally into the 2014 WHO guidelines (10, 12, 13). Steroids are recommended as adjunctive therapy (10, 14).

Published data on management and outcome of paediatric TBM in Europe are limited, and mainly comprise case reports and series from single centres (15-20). This study aimed to describe treatment, outcome, and prognostic factors of TBM in a European cohort of children for whom we have previously reported the performance of immune-based and microbiological diagnostic tests (21).

Methods

Members of the Paediatric Tuberculosis Network European Trials Group (ptbnet) based in Europe, which includes more than 300 clinicians and researchers based in 31 European countries as per November 2020, were invited to retrospectively report all children and
adolescents (0-16 years-of-age) with TBM treated consecutively at their institution between 2006 and 2016. The study opened in February 2016, and reporting closed in August 2016. Anonymized data were collected via a web-based tool that created a standardized dataset for each case. The study approved by the Human Ethics Committee of the Charité University Hospital Berlin and the ptbnet Steering Committee.

**Classification of cases and disease severity**

Disease severity at diagnosis was classified according to MRC Staging (22). Cases were categorised as definite, probable and possible TBM according to previously published criteria with minor modification, as previously described (21, 23). Briefly, to be eligible for inclusion cases had to meet the clinical entry criteria (presence of symptoms and signs of meningitis), and achieve a Uniform Tuberculous Meningitis Research Case Definition Criteria (UTMRCD) score of $\geq 6$ (supplementary material).

**Classification of outcome**

The following parameters were collected to assess outcome at the end of treatment: paresis of $\geq 1$ limb(s), spasticity, cranial nerve palsy, seizures, hypothalamic/pituitary gland dysfunction, developmental delay, chronic hydrocephalus, vision, hearing or speech impairment, coma or death. Additional data could be provided as free text. For binary logistic regression modelling, patients were grouped as “fully recovered” or “unfavourable outcome”, the latter if any long-term sequelae or death occurred.

**Assessment of drug dosing**

Drug dosages were assessed according to the 2010/2014 WHO dosing guidelines for children admitted after 31/12/2010, and according to the 2006 guidelines for children admitted up to that date (10, 12). Currently, the recommended doses for TBM treatment with the WHO 12-month regimen are: INH 10mg/kg (range 7–15mg/kg, maximum 300mg/d), RMP 15mg/kg (10–20mg/kg, maximum 600mg/d), PZA 35mg/kg (30–40mg/kg) and EMB 20mg/kg (15–25mg/kg) (10, 13). The 2010 Rapid Advice differed only in the recommended range for INH (10–15mg/kg). The recommended doses in the 2006 guidelines were: INH 5mg/kg (4–6mg/kg), RMP 10mg/kg (8–12mg/kg), and PZA 25mg/kg (20–30mg/kg), with the same EMB dosing. Patients with higher bodyweight, in whom the maximum daily dose based on mg/kg would be
exceeded, were excluded from this particular analysis. Regarding corticosteroids, currently recommended daily doses of dexamethasone are 0.6mg/kg and prednisone 2–4mg/kg (10, 14). For all corticosteroids used, the prednisolone equivalent dose was calculated (24).

**Statistical analysis**

Data analyses were conducted with SPSS (V25; IBM, Armonk, NY, U.S.). Patient characteristics are presented as median and interquartile ranges (IQR), and qualitative data as frequencies (number and percentage of patients). When specific data were not available for all patients, the denominator is specified. For analyses of the time between hospital admission and cerebral spinal fluid (CSF) examination, cranial imaging or initiation of anti-TB treatment, only cases in whom data were available and the procedures had been performed between the day of admission and the first 70 days were included.

Binary logistic regression modelling was used for bivariate and multivariate analysis to test the effect of covariates as risk factors for unfavourable outcome. Results are presented as unadjusted and adjusted odds ratios (OR) with 95% confidence intervals (95%CI). For the multivariable analysis, only variables with statistical significance from the bivariate analysis, together with age and gender, were included. A two-tailed p-value <0.05 was considered statistically significant.

**Results**

Twenty-seven healthcare centres located in Spain (n=12), Germany, Italy, the United Kingdom (n=3, each), Sweden (n=2), Bulgaria, Finland, Greece, and Slovenia (n=1, each) contributed cases. A total of 118 children fulfilled the inclusion criteria and were included in the final analysis; one submitted case was excluded as it did not reach the minimum UTMRCD score. The median age was 2.7 years (IQR:1.1-6.4). Thirty-nine children (33.1%) presented with stage I disease, 68 (57.6%) with stage II, and 11 (9.3%) with stage III. Fifty-four children (45.8%) were categorised as having definite, 38 (32.2%) probable and 26 (22.0%) possible TBM (table 1). Only five had confirmed multidrug-resistant TB (MDR-TB). The demographic data and clinical features of this cohort have previously been detailed (reproduced as table S2, supplementary material) (21).
Time to TBM investigations and treatment initiation

The median time from hospital admission to CSF examination was 1.0 day (IQR: 0.0-4.8 days; n=104), between admission and cranial imaging 2.0 days (IQR: 0.0-7.0; n=70), between hospital admission and initiation of TB treatment 3.0 days (IQR: 1.0-8.8; n=92), and between CSF examination and the initiation of treatment 1.0 day (IQR: 0.0-4.0; n=101). Time between admission and treatment initiation varied between disease stages: a median of 5.0 days (IQR: 0-17.0; n=33) in stage I disease, 3.0 (IQR: 1.0-10.0; n=63) days in stage II, and 4.0 (IQR: 0.5-4.5; n=9) days in stage III (p=0.223). The time between admission and treatment initiation was 2.0 days (IQR: 0.0-8.0; n=39) in children who fully recovered, and 4.0 days in children with unfavourable outcome (IQR: 1.0-11.0; n=47; p=0.431) (Figure 1).

Antituberculosis treatment

The most frequently used initial anti-TB drugs, dosage and duration are shown in table 2. Among 54 children admitted before the end of 2010 in whom both bodyweight and dosing of at least one drug dose were available, 2 (3.7%) were underdosed for one or more anti-TB drugs according to the 2006 WHO dosing recommendations prevalent at the time: one child was underdosed for EMB only and one for both EMB and INH (none underdosed for RMP or PZA). Among 64 patients admitted from 2011 onwards, 18 (28.1%) were underdosed for one or more anti-TB drugs according to the 2010/2014 dosing guidelines used from then onwards: INH in 4 (6.3%) children (using 7mg/kg as lower limit), RMP in 2 (3.1%), PZA in 14 (21.9%), none for EMB. Drug dosing across the entire study population in relation to the 2006 WHO dosing recommendations and the revised 2010/2014 recommendations is shown in Figure S1. Information on dose adjustment with weight gain during the course of therapy is not available.

Twenty-two children were treated for <12 months and three for <6 months (the latter three died before treatment completion). Figure 2 shows the most frequent initial treatment regimens, with 50.4% (58/115) initially receiving standard four-drug combination therapy. In 15 children this regimen was supplemented with streptomycin (SM) (5 children admitted to hospital before 2006) and in eight with amikacin (n=8). Additional anti-TB drugs used included levofloxacin (n=4), ethionamide (n=3), moxifloxacin (n=3), para-aminosalicylic acid (n=1), cycloserine (n=2) and ciprofloxacin (n=1).
**Anti-inflammatory medication**

Overall, 97.4% (113/116) of patients received corticosteroids, mainly dexamethasone (71.6%; n=83/116) or prednisone (19.8%; n=23/116). The median daily dose used initially was 0.57 (IQR: 0.12-0.60) mg/kg for dexamethasone and 1.36 (IQR: 0.74-3.05) mg/kg for prednisone, with 40.9% (34/83) and 26.1% (6/23) children, respectively, receiving doses below the recommended ranges (10). Median duration of the initial course of steroids was 42 days (IQR: 26.5-60.0; n=77). Sixteen patients (13.8%) had more than one course of corticosteroids. Other anti-inflammatory medication used included thalidomide (8.6%; n=10), acetylsalicylic acid (4.3%; n=5), naproxen (1.3%; n=1), dexketoprofen (1.3%; n=1) and infliximab (1.3%; n=1).

**Other adjunctive treatments**

Almost one third of patients (32.8%; 38/116) received anticonvulsive treatment at some stage either as prophylactic or therapeutical treatment of seizures. Close to one third (29.3%; 34/116) received vitamin D, 14.7% (17/116) proton-pump inhibitors and 10.3% (12/116) diuretics.

**Neurosurgical intervention**

Data on neurosurgery were available in 116 patients. Thirty-eight (32.7%) patients underwent one or more neurosurgical interventions, comprising placement of a ventriculo-peritoneal shunt in 97.4% (37/38), granuloma excision in 5.2% (2/38) and other procedures in 10.5% (4/38) children. Only one patient was reported to have received acetazolamide to reduce intracranial pressure prior to surgery.

**Supportive therapy and healthcare facilities**

The majority of children were treated in a hospital ward (87.9%; 102/116) for a median duration of 28 days (IQR: 14.0-78.8 days). Almost half (48.3%; 56/116) were admitted to ICU at some stage, with a median ICU stay of 10.0 days (IQR: 4.5-21.0 days). Of these, 17.8% (10/56) initially presented at TBM stage I, 66.1% (37/56) at stage II and 16.1% (9/56) at stage III. Mechanical ventilation was required in 20.7% (24/116). Other healthcare facilities included rehabilitation centres (20.7%; n=24) and day-care clinics (13.8%; n=16). The most frequently
used supportive measures were physiotherapy (36.3%; n=42), occupational therapy (17.2%; n=20) and speech therapy (20.7%; n=24).

Initial response to treatment and change of medication
Clinical improvement, as determined by the treating physician, occurred in 82.6% (95/115) of the children, of which 8.4% (8/95) showed initial worsening followed by improvement. No improvement or progressive worsening on treatment was observed in 17.4% (20/115; data missing n=3). Anti-TB treatment was changed in 17.2% (20/116), due to adverse events (n=5), detection of drug-resistant *Mycobacterium tuberculosis* (n=5), clinical or radiological deterioration (n=4), or other reasons (n=6).

Outcome
One-hundred-and-four children with available outcome data were followed up for a median of 20.0 months (IQR: 9.0-25.0 months). Ten children died (9.6%) of whom one had MDR-TB. The timepoint of death was available in 5 children: 3 died within the first 4 months of anti-TB therapy; the remaining 2 died at 9 and 12 months. Fewer than half (47.1%; 49/104) of the children made a full recovery, while 55 had an unfavourable outcome (52.9%; 55/104). Detailed information on outcomes is presented in table 3. Almost half of the children (49.2%; 58/118) showed evidence of hydrocephalus on initial imaging, while four (3.4%; 4/118) developed hydrocephalus subsequently. In 12.5% (13/104) hydrocephalus was reported to be still present at the end of therapy although not all patient had neuroimaging at the end of therapy; of those, 46.2% (6/13) had a VP shunt. Of 11 children with hearing impairment, 2 had received SM as part of the initial treatment (none amikacin).

Risk analysis for unfavourable outcome at the end of treatment
The multivariate logistic regression analysis included 104 patients. Tables 4 and 5 show predictor variables of unfavourable outcome and the results of the bivariate and multivariate logistic regression models.

In bivariate analysis, more severe TBM stage at presentation, microbiological confirmation of TBM (ie definite TBM), presence of hydrocephalus on initial imaging, the need for neurosurgical intervention, requiring mechanical ventilation and requiring admission to ICU
were significantly associated with unfavourable outcome (table 4). In multivariate analysis, microbiological confirmation of TBM, surgical intervention, and mechanical ventilation remained statistically significantly associated with unfavourable outcome, with TBM stage III approaching statistical significance. No association between INH, RMP and PZA dose and unfavourable outcome was observed (table 5).

Discussion
To our knowledge, this is the largest report focused on treatment and outcome of TBM in children in Europe to date. Our data show that TBM is an extremely severe manifestation of TB disease in European children. More than half of the patients (52.9%) had unfavourable outcomes and close to 10% died.

One notable finding is the considerable heterogeneity in the drug combinations and dosing of TB medications. While underdosing according the 2006 guidelines in children admitted before 2011 was rare, more than a quarter of children admitted from 2011 onwards were underdosed for at least one anti-TB drug, most commonly for INH and PZA. This finding might reflect challenges in implementing the new guidelines, potentially resulting from the lack of appropriate pediatric fixed-dose combinations, as previously highlighted (25).

Notably, recent pharmacokinetic data suggest that INH doses >10-15 mg/kg may be required in children with TBM, particularly with higher doses needed per weight <10kg (26). For PZA and RMP, doses at the higher end of the recommended range have also been advocated for children with TBM (27-31), partly as there are data in adults with TBM suggesting that increased dosing of RMP (35mg/kg or even higher) may be associated with a survival benefit (32-34). Nevertheless, in the statistical analysis, we did not find an association between INH, RMP and PZA dosing and unfavourable outcome.

Some guidelines recommend SM or another aminoglycoside as a fourth or fifth drug in the initial treatment of TBM (35). Aminoglycosides penetrate the CSF poorly once inflammation subsides, and have a substantial risk of nephro- and ototoxicity, although we observed
relatively low rates in our study (22, 36-38). Despite its disadvantageous side effect profile, SM was used in >20% of children in our study (27, 29).

While INH and PZA penetrate the CSF well, RMP diffusion is markedly reduced in uninflamed meninges (26, 39). EMB also crosses the blood-brain-barrier poorly (26). A South African group has been advocating a 6-month intensified 4-drug regimen for drug-susceptible TBM since long before its adoption as an alternative regimen by WHO in 2021, comprising INH (20mg/kg), RMP (20mg/kg), PZA (40mg/kg) and ethionamide (20mg/kg), which has good CSF penetration, instead of EMB (28, 40). Thirteen children in our cohort received a regimen that included ethionamide or prothionamide – the propyl analog of ethionamide. The quinolones levofloxacin and moxifloxacin have been considered a valuable alternative (41-45) and paediatric studies are currently ongoing (TBM-KIDS: https://clinicaltrials.gov/ct2/show/NCT02958709 and SURE: http://www.isrctn.com/ISRCTN40829906 ). Linezolid, an agent with good CNS penetration, is also currently being investigated as TBM treatment in adults (SIMPLE study:NCT03537495, Laser TBM:NCT03927313, ALTER:NCT04021121, INTENSE-TBM:NCT04145258). In our cohort, anti-TB drugs were tolerated well overall, with treatment changes due to side effects being required in <5% of patients.

Adjunctive anti-inflammatory therapy forms an essential part of TBM treatment. A Cochrane review conducted in 2008 and updated in 2016 found that steroid use in TBM reduces the risk of death significantly (46, 47). The large majority of children in our cohort received either prednisone or dexamethasone, but in a substantial proportion the doses used were lower than recommended. Thalidomide is sometimes used in TBM treatment due to its anti-inflammatory and immunomodulatory properties, and was given to 10 patients in our cohort, 9 of whom also received corticosteroids (48-50).

The patient outcomes in our cohort illustrate the high mortality and morbidity associated with TBM, even in high-income settings. A recent meta-analysis on childhood TBM, which included data from 19 studies, reported a pooled mortality rate of 20%, substantially higher than the mortality rate observed in our cohort (9.6%) (9). However, the meta-analysis only included 6 studies from low TB incidence, high-resource countries, and those studies contributed fewer
than a quarter of the patients included in the analyses (361 of 1636). Also, almost half of the patients included had stage III disease (n=307 (47%) of 657 patients in whom disease stage was reported), compared with only 9.3% in our cohort. Furthermore, none of the children in our cohort had a known immunodeficiency, contrasting with studies in high TB incidence countries with comparatively high rates of HIV-/TB-co-infection. Finally, it appears likely that the greater availability of ICU support in our high-resource setting played a substantial role. Notably, almost half of the patients in our cohort were treated in an ICU, and about a fifth required mechanical ventilation. While admission to ICU may be a precautionary measure in settings with limited TBM expertise, the need for mechanical ventilation reflects severity of disease better and was associated with unfavourable outcome in our study. We observed a high rate of neurosurgical interventions, also likely reflecting the severity of the disease. In our study, a significant proportion of patients had a seizure disorder at the end of treatment requiring long-term anticonvulsant therapy, which aligns with previous data (51-53). Long-term rehabilitation, such as speech therapy and physiotherapy, was also frequently required.

Fewer than half of the children had fully recovered at the end of treatment, despite <10% of the cohort having presented at stage III disease. Studies from high incidence countries report comparable numbers of children with full recovery, despite a higher proportion of children presenting at an advanced disease stage (5, 6, 9). This might be due to differences in the definition of outcome variables, the assessment procedures used and the duration of follow-up between contributing centers. However, our data indicate that full recovery is less likely in children with more advanced disease (ie stage II and stage III disease) than in those presenting earlier (ie at stage I disease). In the aforementioned South African cohort receiving short intensified treatment, 43% of the children showed full recovery, and 37% had only mild impairment, despite 35% presenting with stage III TBM (28).

Delays in treatment initiation can negatively impact on the outcome of TBM (7, 9). Although the time between hospital admission and treatment initiation was shorter in children who fully recovered compared to children with long-term sequelae, this did not reach statistical significance in the bivariate analysis. A recent single-center study on TBM in children from China reported that raised CSF protein concentrations were linked to poor outcome, which we did not observe in our cohort (54). However, we identified definite diagnosis of TBM as a
risk factor for unfavorable outcome in both bi- and multivariate analyses. This could be due to those patients having more advanced disease with higher bacterial burden overall. Support for this hypothesis lies in the observation that microbiological confirmation was achieved in 63.6% (7/11) of patients with stage III disease, compared with only 34.2% (13/38) in those with stage I disease (table 1).

Our study has some limitations. Most importantly, the retrospective study design carries the risk of recall and selection bias. There were also incomplete data available for some variables. The long duration of the study period and inclusion of sites in several countries resulted in the ability to compile a large cohort with this relatively uncommon condition in Europe, but there was considerable variation in clinical practice and local and international guidelines over the study period.

Our data highlight substantial heterogeneity in paediatric TBM treatment in the European setting in recent years. The associated morbidity and mortality were considerable, despite the widespread availability of ICU and neurosurgical support. Early consideration of TBM in the differential diagnosis, application of up-to-date pharmacokinetic data, data on new or repurposed drugs and multidisciplinary management are essential to optimize treatment. The combination of prospective case registries by research collaborations, such as ptbnet, and the results of currently ongoing TBM treatment trials in children, will hopefully provide further insights helping to improve patient outcomes.
**Author’s contributions:** ST and RK conceived of the study. ST, DBG, BSG, MTs, MTe, and RK designed the study and collected the data. ST and RS performed the data analyses. LFN, ON, ANJ, CL, LG, EV, DB, FG, RK, NMA, SV, FB, RB, SBW, MTs and MTe contributed data, reviewed the data and provided input. ST, RB and RK wrote the first draft of the manuscript. All authors and collaborators have reviewed the paper and have provided comments, and have approved the final version of the manuscript for submission.

**Funding information:** This project was carried out without dedicated funding. Ptbnet is supported by the Deutsche Gesellschaft für Internationale Zusammenarbeit. MTe was supported by a Clinical Lectureship provided by the UK National Institute for Health Research (NIHR), and by a grant from the Technology Strategy Board / Innovate UK. RB is funded by an NIHR Academic Clinical Lectureship at the London School of Hygiene & Tropical Medicine (CL-2018-20-001). ANJ was supported by Subvencions per a la Intensificació de Facultatius Especialistes (Departament de Salut de la Generalitat de Catalunya, Programa PERIS 2016–2020; ref. SLT008/18/00193). ON is supported by Consejería de Salud y Familias, Servicio Andaluz de Salud 2020 (A1-0049-2020).

**Potential conflicts of interest:** MTe has received QuantIFERON assays at reduced pricing or free of charge for other TB diagnostics projects from the manufacturer (Cellestis/Qiagen), and has received support for conference attendance from Cepheid. BGS has received diagnostic assays free of charge for other projects from Cepheid, and support for conference attendance from GlaxoSmithKline (GSK). DBG has received payments as speaker at conferences from MSD and Roche. MTs has received payments from MSD, Pfizer, Sanofi-Pasteur, and GSK for other clinical studies and participation in advisory boards. The other authors report no conflicts of interest.
Figures and tables

Table 1  Disease stage at presentation and degree of certainty of TB meningitis diagnosis*

<table>
<thead>
<tr>
<th></th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite TBM</td>
<td>13 (24.1%)</td>
<td>34 (63.0%)</td>
<td>7 (13.0%)</td>
<td>54</td>
</tr>
<tr>
<td>Probable TBM</td>
<td>14 (36.8%)</td>
<td>20 (52.6%)</td>
<td>4 (10.5%)</td>
<td>38</td>
</tr>
<tr>
<td>Possible TBM</td>
<td>11 (42.3%)</td>
<td>15 (57.7%)</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td>Total</td>
<td>38</td>
<td>69</td>
<td>11</td>
<td>118</td>
</tr>
</tbody>
</table>

* based on Basu Roy et al. (21)
Table 2 Anti-tuberculosis drugs used, drug dosing during initial treatment and treatment duration in the entire cohort (n=118)

<table>
<thead>
<tr>
<th>Anti-TB drug</th>
<th>No. of patients receiving drug</th>
<th>No. of patients with drug dose available</th>
<th>Median dose in mg/kg (IQR)</th>
<th>No. of patients with treatment duration available</th>
<th>Median treatment duration in months (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>115 (97.5%)</td>
<td>70*</td>
<td>10.0 (5.9-11.1)</td>
<td>73</td>
<td>12.0 (9.0-12.0)</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>115 (97.5%)</td>
<td>72**</td>
<td>13.6 (10.0-16.5)</td>
<td>70</td>
<td>12.0 (8.0-12.0)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>114 (96.6%)</td>
<td>69</td>
<td>30.0 (27.8-34.7)</td>
<td>69</td>
<td>2.0 (2.0-4.0)</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>87 (73.7%)</td>
<td>53</td>
<td>20.8 (18.5-25.0)</td>
<td>55</td>
<td>2.0 (2.0-3.0)</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>27 (22.9%)</td>
<td>21</td>
<td>20.0 (20.0-20.0)</td>
<td>27</td>
<td>2.0 (1.0-2.0)</td>
</tr>
<tr>
<td>Amikacin</td>
<td>12 (10.2%)</td>
<td>4</td>
<td>16.1 (15.0-21.0)</td>
<td>12</td>
<td>1.0 (1.0-2.0)</td>
</tr>
<tr>
<td>Prothionamide</td>
<td>10 (8.5%)</td>
<td>9</td>
<td>15.4 (13.6-18.9)</td>
<td>7</td>
<td>3.0 (2.0-3.0)</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>4 (3.4%)</td>
<td>4</td>
<td>12.1 (3.7-15.8)</td>
<td>4</td>
<td>3.0 (1.2-19.0)</td>
</tr>
<tr>
<td>Ethionamide</td>
<td>3 (2.5%)</td>
<td>2</td>
<td>22.50 (n.a.)</td>
<td>3</td>
<td>5.0 (n.a.)</td>
</tr>
<tr>
<td>Moxifloxacine</td>
<td>3 (2.5%)</td>
<td>3</td>
<td>9.5 (n.a.)</td>
<td>3</td>
<td>8.0 (n.a.)</td>
</tr>
</tbody>
</table>

* Isoniazid drug dose available for 76 patients, but 6 patients excluded because the maximum daily dose recommendations of INH 300 mg would be exceeded if dosing was based on mg/kg according to the new WHO guidelines (10).
** Rifampicin drug dose available for 75 patients, but 3 patients excluded because the maximum daily dose recommendations of RMP 600 mg would be exceeded if dosing was based on mg/kg according to the new WHO guidelines (10).
IQR = interquartile range; n.a. = not applicable; no. = number.
Figure 1 Comparison of time from hospital admission to initiation of treatment in children with unfavourable outcome and those with full recovery grouped according to MRC TBM staging. MRC = Medical Research Council.
Figure 2 Most commonly used initial treatment regimens in the study population. INH (isoniazid), RMP (rifampicin), PZA (pyrazinamide), EMB (ethambutol), SM (streptomycin), PTH (prothionamide), AMK (amikacin).
Table 3 Outcomes in 104 children with outcome data available at the end of anti-tuberculosis treatment.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>All patients (n=104)</th>
<th>Patients with possible TBM*** (n=21)</th>
<th>Patients with probable TBM*** (n=35)</th>
<th>Patients with definite TBM*** (n=48)</th>
<th>Patients presenting with stage I disease*** (n=33****)</th>
<th>Patients presenting with stage II disease*** (n=61)</th>
<th>Patients presenting with stage III disease*** (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full recovery</td>
<td>49 (47.1%)</td>
<td>14 (66.7%)</td>
<td>19 (54.3%)</td>
<td>16 (33.3%)</td>
<td>22 (66.7%)</td>
<td>25 (41.0%)</td>
<td>2 (18.2%)</td>
</tr>
<tr>
<td>Spasticity of one or more limbs</td>
<td>20 (19.2%)</td>
<td>1 (4.8%)</td>
<td>5 (14.3%)</td>
<td>14 (29.2%)</td>
<td>4 (12.1%)</td>
<td>12 (19.7%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>20 (19.2%)</td>
<td>0 (0.0%)</td>
<td>7 (20.0%)</td>
<td>13 (27.1%)</td>
<td>2 (6.1%)</td>
<td>12 (19.7%)</td>
<td>6 (60.0%)</td>
</tr>
<tr>
<td>Seizure disorder</td>
<td>18 (17.3%)</td>
<td>1 (4.8%)</td>
<td>3 (8.6%)</td>
<td>14 (29.2%)</td>
<td>2 (6.1%)</td>
<td>12 (19.7%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>Paresis of one or more limbs</td>
<td>15 (14.4%)</td>
<td>0 (0.0%)</td>
<td>4 (11.4%)</td>
<td>11 (22.9%)</td>
<td>1 (3.0%)</td>
<td>10 (16.4%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>Speech impairment</td>
<td>13 (12.5%)</td>
<td>0 (0.0%)</td>
<td>3 (8.6%)</td>
<td>10 (20.8%)</td>
<td>1 (3.0%)</td>
<td>9 (14.8%)</td>
<td>3 (30.0%)</td>
</tr>
<tr>
<td>Visual impairment</td>
<td>14 (13.5%)</td>
<td>1 (4.8%)</td>
<td>3 (8.6%)</td>
<td>10 (20.8%)</td>
<td>0 (0.0%)</td>
<td>10 (16.4%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>Chronic hydrocephalus</td>
<td>13 (12.5%)</td>
<td>1 (4.8%)</td>
<td>2 (5.7%)</td>
<td>10 (20.8%)</td>
<td>4 (12.1%)</td>
<td>5 (8.2%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>Hearing impairment</td>
<td>11 (10.6%)</td>
<td>0 (0.0%)</td>
<td>3 (8.6%)</td>
<td>8 (16.7%)</td>
<td>0 (0.0%)</td>
<td>8 (13.1%)</td>
<td>3 (30.0%)</td>
</tr>
<tr>
<td>Cranial nerve palsy</td>
<td>8 (7.7%)</td>
<td>1 (4.8%)</td>
<td>2 (5.7%)</td>
<td>5 (10.4%)</td>
<td>0 (0.0%)</td>
<td>5 (8.2%)</td>
<td>3 (30.0%)</td>
</tr>
<tr>
<td>Neuroendocrine dysfunction</td>
<td>7 (6.7%)</td>
<td>0 (0.0%)</td>
<td>2 (5.7%)</td>
<td>5 (10.4%)</td>
<td>0 (0.0%)</td>
<td>4 (6.6%)</td>
<td>3 (30.0%)</td>
</tr>
<tr>
<td>Persistent coma*</td>
<td>3 (2.9%)</td>
<td>0 (0.0%)</td>
<td>1 (2.9%)</td>
<td>2 (4.2%)</td>
<td>0 (0.0%)</td>
<td>2 (3.3%)</td>
<td>1 (10.0%)</td>
</tr>
<tr>
<td>Outcome other**</td>
<td>11 (10.6%)</td>
<td>3 (14.3%)</td>
<td>5 (14.3%)</td>
<td>5 (10.4%)</td>
<td>4 (12.1%)</td>
<td>5 (8.2%)</td>
<td>4 (40.0%)</td>
</tr>
<tr>
<td>----------------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Patient died</td>
<td>10 (9.6%)</td>
<td>3 (14.3%)</td>
<td>3 (8.6%)</td>
<td>4 (8.3%)</td>
<td>1 (3.0%)</td>
<td>7 (11.5%)</td>
<td>2 (20.0%)</td>
</tr>
</tbody>
</table>

* One child was comatose at the end of treatment and died following 12 months of treatment.

** Includes mood disorders, behavioral, memory and school difficulties, urinary incontinence, and narcolepsy.

*** based on Basu Roy et al. (21)
Table 4 Bivariate regression analysis of risk factors for unfavourable outcome in 104 patients with available data on outcome. Statistically significant values are highlighted in bold.

<table>
<thead>
<tr>
<th>Predictor variable</th>
<th>Unadjusted odds ratio</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male)</td>
<td>1.369</td>
<td>0.632-2.965</td>
<td>0.426</td>
</tr>
<tr>
<td>Age at hospital admission</td>
<td>0.953</td>
<td>0.875 – 1.038</td>
<td>0.268</td>
</tr>
<tr>
<td>BCG vaccination</td>
<td>1.046</td>
<td>0.364 – 3.008</td>
<td>0.934</td>
</tr>
<tr>
<td>TBM stage I</td>
<td>Ref.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TBM stage II</td>
<td>2.880</td>
<td>1.188 – 6.982</td>
<td>0.019</td>
</tr>
<tr>
<td>TBM stage III</td>
<td>8.000</td>
<td>1.447 – 44.240</td>
<td>0.017</td>
</tr>
<tr>
<td>Possible TBM</td>
<td>Ref.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Probable TBM</td>
<td>1.684</td>
<td>0.547-5.187</td>
<td>0.364</td>
</tr>
<tr>
<td>Definite TBM</td>
<td>4.000</td>
<td>1.348-11.871</td>
<td>0.012</td>
</tr>
<tr>
<td>Time from admission to start of treatment [d]</td>
<td>1.006</td>
<td>0.965 – 1.049</td>
<td>0.769</td>
</tr>
<tr>
<td>Leukocytes count in initial CSF sample [/µl]</td>
<td>1.000</td>
<td>0.999 – 1.001</td>
<td>0.731</td>
</tr>
<tr>
<td>Neutrophil percentage in initial CSF sample</td>
<td>0.993</td>
<td>0.974 - 1.012</td>
<td>0.491</td>
</tr>
<tr>
<td>Protein concentration in initial CSF sample [g/l]</td>
<td>0.951</td>
<td>0.863 – 1.049</td>
<td>0.318</td>
</tr>
<tr>
<td>Glucose concentration in initial CSF sample &lt;2.2mmol/l</td>
<td>2.182</td>
<td>0.879-5.414</td>
<td>0.092</td>
</tr>
<tr>
<td>RMP dose [mg/kg] during initial treatment</td>
<td>0.973</td>
<td>0.859 – 1.102</td>
<td>0.666</td>
</tr>
<tr>
<td>INH dose [mg/kg] during initial treatment</td>
<td>0.923</td>
<td>0.804 – 1.060</td>
<td>0.254</td>
</tr>
<tr>
<td>PZA dose [mg/kg] during initial treatment</td>
<td>0.961</td>
<td>0.874-1.056</td>
<td>0.410</td>
</tr>
<tr>
<td>Steroid dose (prednisolone equivalent) [mg/kg]</td>
<td>1.241</td>
<td>0.924 - 1.666</td>
<td>0.152</td>
</tr>
<tr>
<td>Hydrocephalus on initial imaging</td>
<td>2.556</td>
<td>1.159 - 5.640</td>
<td>0.020</td>
</tr>
<tr>
<td>Neurosurgical intervention</td>
<td>5.182</td>
<td>2.191 - 12.258</td>
<td>0.000</td>
</tr>
<tr>
<td>Mechanical ventilation required</td>
<td>5.033</td>
<td>1.559 – 16.243</td>
<td>0.007</td>
</tr>
<tr>
<td>Admission to intensive care unit</td>
<td>2.197</td>
<td>1.001-4.820</td>
<td>0.050</td>
</tr>
</tbody>
</table>

BCG = *Bacillus Calmette-Guérin*; CI = confidence interval; CSF = cerebrospinal fluid; d = days; INH = isoniazid; RMP = rifampicin; TBM = tuberculous meningitis.
Table 5 Multivariate regression analysis of risk factors for unfavourable outcome in 104 patients with available data on outcome. Statistically significant values are highlighted in bold.

<table>
<thead>
<tr>
<th>Predictor variable</th>
<th>Adjusted odds ratio</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male)</td>
<td>2.248</td>
<td>0.838-6.029</td>
<td>0.107</td>
</tr>
<tr>
<td>Age at hospital admission</td>
<td>0.995</td>
<td>0.895-1.106</td>
<td>0.924</td>
</tr>
<tr>
<td>TBM stage I</td>
<td>Ref.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TBM stage II</td>
<td>2.683</td>
<td>0.866-8.313</td>
<td>0.087</td>
</tr>
<tr>
<td>TBM stage III</td>
<td>7.810</td>
<td>0.815-74.837</td>
<td>0.075</td>
</tr>
<tr>
<td>Possible TBM</td>
<td>Ref.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Probable TBM</td>
<td>2.609</td>
<td>0.622-10.938</td>
<td>0.190</td>
</tr>
<tr>
<td>Definite TBM</td>
<td>5.862</td>
<td>1.349-25.470</td>
<td>0.018</td>
</tr>
<tr>
<td>Hydrocephalus on initial imaging</td>
<td>1.001</td>
<td>0.359-2.795</td>
<td>0.998</td>
</tr>
<tr>
<td>Neurosurgical intervention</td>
<td>4.408</td>
<td>1.364-14.241</td>
<td>0.013</td>
</tr>
<tr>
<td>Mechanical ventilation required</td>
<td>5.601</td>
<td>1.143-27.452</td>
<td>0.034</td>
</tr>
<tr>
<td>Admission to intensive care unit</td>
<td>0.273</td>
<td>0.072-1.044</td>
<td>0.058</td>
</tr>
</tbody>
</table>

CI = confidence interval; TBM = tuberculous meningitis.
References


